{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T12:01:04Z","timestamp":1772366464097,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.lungcan.2017.05.012","type":"journal-article","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T17:45:43Z","timestamp":1494611143000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial"],"prefix":"10.1016","volume":"110","author":[{"given":"Mei","family":"Zhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanrui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.lungcan.2017.05.012_bib0005","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2017.05.012_bib0010","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1080\/10408440903044928","article-title":"Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005","volume":"39","author":"Price","year":"2009","journal-title":"Crit. Rev. Toxicol."},{"issue":"4","key":"10.1016\/j.lungcan.2017.05.012_bib0015","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1289\/ehp.1002845","article-title":"Global magnitude of reported and unreported mesothelioma","volume":"119","author":"Park","year":"2011","journal-title":"Environ. Health Perspect."},{"issue":"12","key":"10.1016\/j.lungcan.2017.05.012_bib0020","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1289\/ehp.11272","article-title":"Recent mortality from pleural mesothelioma, historical patterns of asbestos use, and adoption of bans: a global assessment","volume":"116","author":"Nishikawa","year":"2008","journal-title":"Environ. Health Perspect."},{"issue":"4","key":"10.1016\/j.lungcan.2017.05.012_bib0025","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1179\/oeh.2007.13.4.398","article-title":"Incidence and descriptive epidemiology of mesothelioma in the United States, 1999\u20132002","volume":"13","author":"Larson","year":"2007","journal-title":"Int. J. Occup. Environ. Health"},{"issue":"2","key":"10.1016\/j.lungcan.2017.05.012_bib0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/aje\/kwh025","article-title":"Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003","volume":"159","author":"Price","year":"2004","journal-title":"Am. J. Epidemiol."},{"issue":"3\u20134","key":"10.1016\/j.lungcan.2017.05.012_bib0035","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/sj.bjc.6690105","article-title":"The european mesothelioma epidemic","volume":"79","author":"Peto","year":"1999","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2017.05.012_bib0040","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/ajim.10047","article-title":"Malignant mesothelioma in Australia, 1945\u20132000","volume":"41","author":"Leigh","year":"2002","journal-title":"Am. J. Ind. Med."},{"key":"10.1016\/j.lungcan.2017.05.012_bib0045","series-title":"National Cancer Registry Disease Prevention and Control Bureau, MOH. Chinese Cancer Registry Annual Report (2008\u20132012)","article-title":"National Office for Cancer Prevention and Control","year":"2013"},{"issue":"14","key":"10.1016\/j.lungcan.2017.05.012_bib0050","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"10026","key":"10.1016\/j.lungcan.2017.05.012_bib0055","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"7","key":"10.1016\/j.lungcan.2017.05.012_bib0060","doi-asserted-by":"crossref","first-page":"825","DOI":"10.6004\/jnccn.2016.0087","article-title":"NCCN guidelines insights: malignant pleural mesothelioma, version 3.2016","volume":"14","author":"Ettinger","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw.: JNCCN"},{"issue":"1","key":"10.1016\/j.lungcan.2017.05.012_bib0065","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1586\/14737167.2014.873703","article-title":"Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus","volume":"14","author":"Petrou","year":"2014","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"issue":"2","key":"10.1016\/j.lungcan.2017.05.012_bib0070","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.clinthera.2008.02.013","article-title":"Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland","volume":"30","author":"Purmonen","year":"2008","journal-title":"Clin. Ther."},{"key":"10.1016\/j.lungcan.2017.05.012_bib0075","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1477-7525-6-84","article-title":"Health state utilities for non small cell lung cancer","volume":"6","author":"Nafees","year":"2008","journal-title":"Health Qual. Life Outcomes"},{"issue":"8","key":"10.1016\/j.lungcan.2017.05.012_bib0080","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/codi.12216","article-title":"Cost analysis of adjuvant therapy with XELOX or FOLFOX4 for colon cancer","volume":"15","author":"Xie","year":"2013","journal-title":"Colorectal Dis."},{"issue":"5","key":"10.1016\/j.lungcan.2017.05.012_bib0085","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1524-4733.2004.75003.x","article-title":"Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?","volume":"7","author":"Eichler","year":"2004","journal-title":"Value Health: J. Int. Soc. Pharmacoecon. Outcomes Res."},{"issue":"3","key":"10.1016\/j.lungcan.2017.05.012_bib0090","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O","article-title":"Development of WHO guidelines on generalized cost-effectiveness analysis","volume":"9","author":"Murray","year":"2000","journal-title":"Health Econ."},{"issue":"10","key":"10.1016\/j.lungcan.2017.05.012_bib0095","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2014.58.4904","article-title":"First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis","volume":"33","author":"Goldstein","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2017.05.012_bib0100","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3892\/ol.2016.4871","article-title":"Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences","volume":"12","author":"Ruiz-Sanchez","year":"2016","journal-title":"Oncol. Lett."},{"issue":"5","key":"10.1016\/j.lungcan.2017.05.012_bib0105","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1464-410X.2010.09957.x","article-title":"Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma","volume":"108","author":"Benedict","year":"2011","journal-title":"BJU Int."},{"issue":"3","key":"10.1016\/j.lungcan.2017.05.012_bib0110","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ygyno.2015.02.027","article-title":"A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer","volume":"137","author":"Minion","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2017.05.012_bib0115","doi-asserted-by":"crossref","first-page":"A461","DOI":"10.1016\/j.jval.2015.09.1193","article-title":"Adding bevacizumab to single-agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: a cost-effectiveness analysis of the aurelia trial","volume":"18","author":"Schaffer","year":"2015","journal-title":"Value Health: J. Int. Soc. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.lungcan.2017.05.012_bib0120","first-page":"9","article-title":"Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review","volume":"7","author":"Chouaid","year":"2015","journal-title":"ClinicoEcon. Outcomes Res.: CEOR"},{"issue":"8","key":"10.1016\/j.lungcan.2017.05.012_bib0125","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: aVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217303318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217303318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T03:00:41Z","timestamp":1719198041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500217303318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":25,"alternative-id":["S0169500217303318"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.05.012","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}